The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea.
Roche has launched what it says is a first-of-its-kind handheld glucose management device, backed up by a digital platform that aims to simplify the work of doctors and nurses as they deliv
Merck & Co's Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but was leapfrogged by Roche's Tecentriq in the early-stage, adjuvant trea